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Introduction: Chemotherapy remains the only available treatment for triple-negative (TN) breast cancer, and most
patients exhibit an incomplete pathologic response. Half of patients exhibiting an incomplete pathologic response
die within five years of treatment due to chemo-resistant, recurrent tumor growth. Defining molecules responsible
for TN breast cancer chemo-resistance is crucial for developing effective combination therapies blocking tumor
recurrence. Historically, chemo-resistance studies have relied on long-term chemotherapy selection models that
drive genetic mutations conferring cell survival. Other models suggest that tumors are heterogeneous, being
composed of both chemo-sensitive and chemo-resistant tumor cell populations. We previously described a short-term
chemotherapy treatment model that enriches for chemo-residual TN tumor cells. In the current work, we use this
enrichment strategy to identify a novel determinant of TN breast cancer chemotherapy resistance [a nuclear isoform
of basic fibroblast growth factor (bFGF)].
Methods: Studies are conducted using our in vitro model of chemotherapy resistance. Short-term chemotherapy
treatment enriches for a chemo-residual TN subpopulation that over time resumes proliferation. By western blotting
and real-time polymerase chain reaction, we show that this chemotherapy-enriched tumor cell subpopulation
expresses nuclear bFGF. The importance of bFGF for survival of these chemo-residual cells is interrogated using short
hairpin knockdown strategies. DNA repair capability is assessed by comet assay. Immunohistochemistry (IHC) is used to
determine nuclear bFGF expression in TN breast cancer cases pre- and post- neoadjuvant chemotherapy.
Results: TN tumor cells surviving short-term chemotherapy treatment express increased nuclear bFGF. bFGF
knockdown reduces the number of chemo-residual TN tumor cells. Adding back a nuclear bFGF construct to bFGF
knockdown cells restores their chemo-resistance. Nuclear bFGF-mediated chemo-resistance is associated with increased
DNA-dependent protein kinase (DNA-PK) expression and accelerated DNA repair. In fifty-six percent of matched TN
breast cancer cases, percent nuclear bFGF-positive tumor cells either increases or remains the same post- neoadjuvant
chemotherapy treatment (compared to pre-treatment). These data indicate that in a subset of TN breast cancers,
chemotherapy enriches for nuclear bFGF-expressing tumor cells.
Conclusion: These studies identify nuclear bFGF as a protein in a subset of TN breast cancers that likely contributes to
drug resistance following standard chemotherapy treatment.* Correspondence: robin.bachelder@duke.edu
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Targeted therapies are not available for triple-negative
(TN) breast cancer, which lacks estrogen receptor,
progesterone receptor, and human epidermal growth factor
receptor-2 (HER2) over-expression. Although TN breast
tumors initially respond to chemotherapy, this response is
incomplete in more than half of these patients [1, 2].
Notably, tumor recurrence is observed within 5 years
of treatment in half of patients exhibiting an incomplete
pathologic response, resulting in patient mortality [3, 4].
Accumulating evidence indicates that a small popula-
tion of drug-resistant tumor cells surviving initial
chemotherapy treatment is likely responsible for tumor
relapse [5–7]. In order to identify new treatment strategies
for these aggressive breast cancers, there is an urgent need
to identify novel signaling pathways that contribute to TN
breast cancer chemo-resistance.
We previously characterized an in vitro model of
chemo-resistance/tumor recurrence [8]. In this model,
tumor cells were subjected to short-term chemotherapy,
which killed 99.9 % of tumor cells. However, a subpopu-
lation (0.1 %) of chemo-resistant tumor cells persisted
and resumed proliferation approximately 2 weeks
after chemotherapy removal. In the current work, we
investigated signaling pathways that drive TN tumor
cell chemo-resistance using this in vitro model.
The basic fibroblast growth factor family (bFGF)
(alternatively known as FGF-2) consists of both cytosolic
(secreted) and nuclear isoforms. Expression of these
bFGF isoforms is regulated at the level of translation.
Specifically, cytosolic forms (low molecular weight, 18 kDa)
are regulated by cap-dependent translation, whereas
nuclear forms (high molecular weight; 22, 22.5, and
24 kDa) are regulated by cap-independent translation
[9]. These isoforms differ in molecular weight because
they utilize different translation initiation sites.
Cytosolic (secreted) isoforms of bFGF are implicated
in tumor resistance to anti-angiogenic therapy [10–15].
However, functions for nuclear bFGF in cancer cells remain
poorly understood. In over-expression models, nuclear
bFGF has been reported to regulate cell cycle [16–18], cell
survival [19], radio-resistance [20], and tumor metastasis
[19, 21]. Moreover, nuclear bFGF expression in astrocytic
tumors is associated with a poor patient prognosis [22]. To
date, nuclear bFGF expression/function in breast cancer
has not been investigated.
DNA repair pathways are frequently de-regulated in
breast cancer. Whereas BRCA proteins are responsible
for homologous repair, DNA-dependent protein kinase
(DNA-PK) repairs double-stranded DNA breaks by non-
homologous end joining. DNA-PK consists of a catalytic
subunit (DNA-PKCS) and a regulatory subunit (Ku70
and Ku80 heterodimer), which recruits DNA-PKCS to
DNA. The status of the cell cycle determines whetherDNA-PK or BRCA repairs DNA, with DNA-PK being
responsible in growth-arrested cells [23].
Previous studies using bFGF over-expression models
suggest that nuclear bFGF drives DNA-PKCS transcription
[20]; however, the ability of endogenous bFGF to regulate
DNA-PKCS expression/DNA repair in tumor cells has not
been reported. In the current work, we show that nuclear
bFGF promotes survival of chemo-residual TN tumor cells.
This bFGF function is associated with increased DNA dam-
age repair mediated by increased DNA-PK expression/ac-
tivity. Our work identifies nuclear bFGF as a central
determinant of TN breast cancer chemo-resistance, and
suggests a novel therapeutic target (nuclear bFGF) for
preventing TN breast cancer recurrence.
Methods
Cell culture
SUM159 TN breast cancer cells were obtained from the
Duke Cell Culture Facility and maintained in Ham’s
F-12 medium containing 5 % heat-inactivated FBS, 5 μg/ml
insulin, and 1 μg/ml hydrocortisone. BT549 TN breast
cancer cells were obtained from the Duke Cell Culture
Facility and maintained in RPMI 1640 medium containing
10 % heat-inactivated FBS, 1 μg/ml insulin, 10 mM HEPES,
1 mM pyruvate, and 2.5 g/L glucose.
Generation of chemo-residual tumor cells and subsequent
colonies
SUM159 tumor cells were seeded in T225 cell culture flasks
(2 × 106 cells/flask) and, after 2 days, treated with either 1 μg/
ml doxorubicin (Sigma, St Louis, MO, USA) or 100 nM do-
cetaxel (Sigma). The drug was removed after 2 days, and cells
were fed new media every third day. The majority of cells
(99.9 %) were eliminated by day 7, after which only chemo-
residual cells (0.1 %) were observed. BT549 tumor cells were
seeded in T225 cell culture flasks (3 × 106 cells/flask) and,
after 2 days, treated with 0.5 μg/ml doxorubicin. Drug was re-
moved after 2 days, and cells were fed new media every third
day. The majority of cells (99.9 %) were eliminated by day 7,
after which only chemo-residual cells (0.1 %) were observed.
SUM159 and BT549 chemo-residual cells were harvested
on day 7 with trypsin-EDTA, and re-plated in 6-well
plates. Resumed proliferation of chemo-residual tumor
cells was monitored over time. Medium was changed
every 3 to 4 days. Colonies evolving from chemo-
residual cells were stained with crystal violet and col-
onies containing >50 cells were counted [24].
For the mammosphere culture, cells were seeded into
Mammacult media (Stem cell Tech., Vancouver, BC,
Canada; #05620) supplemented with 1 % Methylcellulose
(Sigma St Louis, MO, USA; #M0430), penicillin/strepto-
mycin (Life Technologies, Carlsbad, CA, USA), heparin
(Stemcell Tech., #07980; 4 μg/mL), and hydrocortisone
(1 μg/ml). The sphere assay was setup in Costar 6-Well
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cate. Cells were incubated at 37 °C/5 % CO2. Spheres were
counted with a GelCount cell counter (Oxford Optronix,
Milton Park, UK) after 3 to 7 days. For secondary sphere
assays, primary spheres were dissociated with trypsin,
washed, and seeded at 20,000 cells/well as above.Western blots
Cells were harvested using trypsin-EDTA and washed
with PBS. Harvested cells were incubated in cytosolic
lysis buffer (10 mM HEPES (pH 7.4), 10 mM KCl, 1.5
mM MgCl2, 0.5 % NP40, and proteinase inhibitors) on
ice for 20 minutes and centrifuged. Supernatants were
collected as cytosolic protein lysates. The residual pellets
were washed with cytosolic lysis buffer, and then incubated
in nuclear lysis buffer (50 mM TRIS (pH 7.5), 1 % SDS,
and proteinase inhibitors) plus Benzonase (Sigma) on ice
for 20 minutes. The supernatants after centrifugation
were collected as nuclear protein extracts. Protein
concentrations were determined by bicinchoninic acid
(BCA) assay. Equivalent amounts of protein were subjected
to SDS-polyacrylamide gel electrophoresis (PAGE) and
immunoblotted with the following primary antibodies,
followed by the appropriate species IRDye-conjugated
secondary antibody (Life Technologies, Carlsbad, CA,
USA): bFGF (BD Biosciences, Franklin Lakes, NJ, USA;
catalog # 610073), Lamin-A (Sigma), DNA-PKCS (Cell
Signaling, Beverly, MA, USA; catalog # 4602), phospho-
Ser 2056-DNA-PKCS (Cell Signaling, Beverly, MA, USA;
catalog # 4215), GAPDH (GenScript, Piscataway, NJ, USA).
Proteins were detected using Odyssey infrared imaging
system (LI-COR, Lincoln, NE, USA).Immunofluorescence
Cells were grown on glass coverslips, washed with Hanks’
balanced salt solution (HBSS), and fixed for 30 minutes at
room temperature in 1 % fresh formaldehyde in PBS. After
washing for 5 minutes in PBS, the coverslips were incu-
bated in 5 % bovine serum albumin (BSA) in PBS for 90
minutes at room temperature. Excess BSA was drained
from the coverslips, and cells were incubated with the
primary bFGF antibody (BD Biosciences, Franklin Lakes,
NJ, USA) in PBS containing 0.5 % BSA, overnight at 4 °C.
The cells were then rinsed three times in PBS containing
0.1 % Tween and incubated with secondary antibody (1:400
dilution of an Alexa Fluor 568-conjugated donkey anti-
mouse IgG, Life Technologies) for 90 minutes at 4 °C in
the dark. The cells were washed three times with PBS, incu-
bated with a 1:1000 dilution of Hoechst (Life Technologies)
for 10 minutes at room temperature in the dark, and
washed three times with PBS. The coverslips were dried for
2 h at room temperature, mounted, and cured overnight at
4 °C. Pictures were taken using a fluorescence microscopeand analyzed with Gen5 image analysis software (BioTek,
Winooski, VT, USA).
Thymidine uptake
Cells were plated in 96-well plates (3 × 103 cells/well). After
4 h, cells were incubated with 0.5 μCi/well Methyl-[3H]-
Thymidine (Perkin Elmer, Waltham, MA, USA) for 16 h
before harvesting onto glass-fiber filters. [3H]-Thymidine
incorporation was measured as counts per minute (CPM)
using a Tri-Carb 2100TR time-resolved liquid scintillation
counter (Perkin Elmer, Waltham, MA, USA).
Alamar blue
Cells were plated in 96-well black, clear-bottom plates
(2 × 103 cells/well) in 100 μl complete medium. After
4 h, 10 μl/well Alamar Blue (Life Technologies) reagent
was added. After 2 h, fluorescence was measured using a
Cytation3 plate reader (BioTek).
shRNA and addback transfection
Cells were grown to 50 % confluence in a 10-cm dish. The
transfection mixtures contained: 1) 2 μg bFGF shRNA
(Sigma, St. Louis, MO; clone # NM_02006.x-635s1c1;
catalog # TRCN0000003330) or control shRNA plasmid
(Sigma, St Louis, MO, USA; pLKO.1) + Optimem
(Life Technologies) and 2) Lipofectamine 2000 (Life
Technologies) + Optimem. These mixtures were incubated
separately at room temperature for 5 minutes, combined,
and incubated for 30 minutes at room temperature. Cells
were washed twice with HBSS (Life Technologies).
Optimem was then added to the RNA/Lipofectamine
mixture, and the mix was added to the cells, which
were incubated overnight at 37 °C. This medium was
removed the next day and replaced with media containing
puromycin (5 μg/ml, SUM159; 2 μg/ml, BT549). Cells
were expanded in puromycin and tested for bFGF knock-
down by western blotting. For bFGF addback, plasmids
[25] expressing 18-kDa rat bFGF, 23-kDa rat bFGF, or an
empty control vector were transfected into SUM159 or
BT549 cells stably expressing a bFGF shRNA. The trans-
fection protocol was performed as above, except that the
cells were selected in puromycin (as above) and G418
(Life Technologies) at 400 μg/ml. Expression of addback
constructs was assessed by western blotting cell extracts
with bFGF antibody.
Single cell gel electrophoresis assay (comet assay)
Cells were challenged with doxorubicin (SUM159: 1 μg/ml,
3 h; BT549: 0.5 μg/ml, 4h). Fresh medium was added after
chemotherapy removal. Cells were harvested at sequential
time points after chemotherapy, mixed with low-melting-
point agarose, and spread on comet slides using a Trevigen
CometAssay® Kit (Trevigen Inc., Gaithersburg, MD, USA).
After incubation with lysis solution and neutral solution,
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50 minutes under neutral conditions. Slides were incu-
bated with DNA precipitation solution (1 M NH4AC, 95 %
EtOH) for 30 minutes, followed by 70 % ethanol for 30
minutes. Slides were then stained with a 1:500 dilution of
Hoechst (Life Technologies) for 15 minutes and washed
with PBS. Samples were examined using a fluorescence
microscope, and the presence of comet tails was quanti-
fied using Gen5 image analysis software (BioTek). Cells
from three fields were analyzed for each time point. Each
field contained at least 50 cells.
Real-time quantitative RT-PCR
Total RNA from SUM159 cells was extracted using
PrepEase® RNA Spin Kit (USB, Cleveland, OH, USA)
and treated with RNase-free DNase to remove residual
genomic DNA. Single-stranded cDNAs were synthesized
using the iScript cDNA synthesis kit (Bio-Rad, Hercules,
CA, USA). Human fibroblast growth factor-2 (FGF2)
and human DNA-PKcs primers were purchased from
realtimeprimers.com (Elkins Park, PA, USA). Real-time
PCR on the Mx3005P® QPCR System (Stratagene, La
Jolla, CA, USA) was performed in the presence of 12.5
μl VeriQuest™ Fast SYBR Green qPCR Master mix (2×)
(USB, Cleveland, OH), 2 μl cDNA, and H2O added to a
final volume of 25μl. The mixtures were denatured for 5
minutes at 95 °C, followed by 40 cycles of 3 s at 95 °C,
and 30 s at an annealing temperature at 60 °C. PCR
products were monitored in real time by measuring the
increase in fluorescence caused by the binding of
SYBR Green I Dye. Significance was analyzed using
the software package MxPro™ QPCR Software (Stratagene,
La Jolla, CA, USA).
Selective DNA-PK inhibitor (NU7441) studies
Cells were seeded in T225 cell culture flasks (2 × 106 cells/
flask) and, after 2 days, treated with 1 μg/ml doxorubicin
(Sigma) plus dimethyl sulfoxide (DMSO) or NU7441 (1 μM
or 5 μM, R&D Systems, Minneapolis, MN, USA). The drug
was removed after 2 days, and cells were fed with new
medium every third day. Chemo-residual cells were har-
vested on day 7 with trypsin-EDTA, and re-plated in 6-well
plates. Medium was changed every 3 to 4 days. Colonies
evolving from chemo-residual cells were stained with crystal
violet. Colonies containing >50 cells were counted.
Immunohistochemistry of patient tumors
TN breast cancer patients treated with neoadjuvant
chemotherapy that exhibited an incomplete pathologic
response were identified from medical records under
Duke Institutional Review Board approval (protocol
47289). Retrospectively collected tumor biopsies (obtained
pre-chemotherapy) and biopsies/resections (obtained
post-chemotherapy) from these patients were retrieved.Formalin-fixed, paraffin-embedded tissues were subjected
to bFGF immunohistochemistry. Slides were baked at 60 °C
for 1 h, and deparaffinized in xylene followed by 100 %
ethanol. Antigen retrieval was performed in sub-boiling
EDTA (pH 8) at 100 °C for 40 minutes. bFGF staining was
performed in an autostainer according to the following
program: Endogenous Peroxidase Quench (Cell Marque
Rocklin, CA, USA) 5 minutes; Protein block (Biocare
Medical, Concord, CA, USA), 10 minutes; bFGF antibody
(BD Biosciences, Franklin Lakes, NJ, USA; catalog #
610073 (1:250 dilution), 1 h; secondary detection kit (Cell
Marque, Rocklin, CA, USA), 20 minutes; 3,3-diaminoben-
zidine (DAB), 5 minutes; hematoxylin, 1 minute; and Blu-
ing, 1 minute. Slides were then placed in water and
dehydrated in xylene before adding a coverslip.
bFGF immunohistochemistry scoring
Two pathologists (GD, RA) (blinded to patient samples)
assigned scores for the percentage of nuclear bFGF-positive
cells and percentage of cytosolic bFGF-positive cells. The
scoring of all cases was confirmed by a board-certified
pathologist (SVP).
Results
Chemo-residual TN breast cancer cells express increased
nuclear bFGF
To enrich for chemo-resistant tumor cells, we treated
SUM159 and BT549 TN breast tumor cells with doxorubi-
cin at a clinically relevant concentration [26]. Doxorubicin
was removed after 2 days, and fresh medium was added.
Although the vast majority of cells were eliminated by day
6, we observed a small number of residual, viable tumor
cells, representing 0.1 % of the original population, on day
7 post treatment (Fig. 1a). These chemo-residual cells were
metabolically active, but exhibited significantly reduced
proliferation (Fig. 1b). Chemo-residual tumor cells re-
sumed proliferation approximately 2 weeks post chemo-
therapy treatment. Our previous studies show that
colonies from this model continue to expand after 18
days, and exhibit resistance to multiple classes of chemo-
therapy for as long as 50 days [8].
Previous studies suggest that continuous chemother-
apy selection models promote the growth of cancer
stem-like cells [27–29]. Accordingly, we investigated if
chemo-residual tumor cells from our short-term chemo-
therapy treatment model behaved like cancer stem-like
cells. As shown in Fig. 1c, d, chemo-residual TN tumor cells
in our model did not exhibit increased mammosphere-
forming ability. Continuous chemotherapy treatment of
TN breast cancer cells has also been shown to drive
hypoxia inducible factor-1α (HIF-1α) expression, a critical
determinant of cancer stemness [28]. In contrast, chemo-
residual tumor cells emanating from our short-term
chemotherapy treatment model exhibited reduced HIF-1α
Fig. 1 (See legend on next page.)
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Fig. 1 Chemo-residual triple-negative (TN) breast tumor cells emanating from a short-term chemotherapy treatment model do not exhibit
cancer stem-like cell behavior. a In vitro model of TN breast cancer chemo-resistance. SUM159 and BT549 tumor cells were treated with
doxorubicin (Dox) (1 μg/ml, 0.5 μg/ml, respectively) for 2 days, after which chemotherapy was removed and fresh medium was added. Between 7
and 10 days, a small number of chemo-residual cells (0.1 % of the original population) remained, and exhibited reduced proliferation compared
to parental (untreated) cells. Approximately 2 weeks after chemotherapy withdrawal, chemo-residual cells resumed proliferation and established
colonies. Pictures of parental (untreated) cells, chemo-residual cells, and colonies emanating from chemo-residual cells were taken on days 0, 7,
14 (SUM159 cells) or days 0, 10, 18 (BT549 cells), respectively. Magnification ×200. Similar data were obtained by treating SUM159 cells with
docetaxel (100 nM) for 2 days [8]. b SUM159 cells were treated with Dox as described in Fig. 1a. Parental and chemo-residual cells were seeded at
equal density in a 96-well plate. Left panel: proliferation was determined by 3H-thymidine incorporation. Right panel: cell viability was assessed by
alamar blue. Error bars represent SD, n = 6, ***p <0.001, two-tailed Student’s t test. c SUM159 parental and chemo-residual cells harvested on day
7 after Dox treatment were seeded at the indicated numbers into a mammosphere assay. Mammosphere number was quantified after 4 days.
Error bars represent SD, n = 3, **p <0.01, ***p <0.001, two-tailed Student’s t test. d Parental and chemo-residual cells harvested on day 8 after
docetaxel treatment were seeded into a mammmosphere assay. Mammosphere number was quantified after 4 days. Error bars represent SD,
n = 3, ***p <0.001, two-tailed Student’s t test. e RNA was extracted from SUM159 parental and chemo-residual cells harvested on day 7 after Dox
treatment. Equivalent amounts were subjected to hypoxia inducible factor-1α (HIF-1α) real-time PCR. Results are expressed as the mean HIF-1α/
β- actin ratio from triplicate wells (+/- SD). **p <0.01, two-tailed Student’s t test. f Total cellular extracts obtained from SUM159 parental and
chemo-residual cells harvested on day 7 after Dox treatment were subjected to SDS-PAGE and immunoblotted with a HIF-1α or β-actin antibody,
followed by secondary antibody
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these findings suggest that chemo-residual tumor cells
evolving from our short-term chemotherapy treatment
model are different from previously defined cancer
stem-like cells selected by continuous chemotherapy
treatment models.
bFGF signaling has been implicated in tumor resistance
to targeted therapies [10–15]. Accordingly, we investigated
bFGF expression in chemo-residual TN tumor cells from
our short-term chemotherapy treatment model. As shown
in Fig. 2a, we observed significantly increased bFGF mRNA
expression in chemo-residual tumor cells compared to
parental cells. To further elucidate the connection between
different isoforms of bFGF and chemo-resistance, we mea-
sured nuclear and cytosolic bFGF levels in chemo-residual
TN tumor cells. On western blots, significantly increased
levels of nuclear bFGF isoforms (22, 24 kDa), but not the
cytosolic bFGF isoform (18 kDa), were detected in chemo-
residual cells compared to parental cells (Fig. 2b). This
trend was observed regardless of the chemotherapy class
studied (doxorubicin or docetaxel, Fig. 2b). By immuno-
fluorescence, we confirmed increased nuclear bFGF in
chemo-residual cells relative to parental cells for both
SUM159 and BT549 TN breast cancer cells (Fig. 2c) and
for two other TN breast cancer cell lines (HS578T and
MDA-MB-231, data not shown). These results suggest an
association between nuclear bFGF expression and TN
breast cancer chemo-resistance.bFGF is essential for the survival of chemo-residual tumor
cells and subsequent colony formation
Studies in Fig. 2 indicate that nuclear bFGF is upregulated
in chemo-residual TN breast cancer cells. To determine
whether bFGF is required for TN breast cancer chemo-
resistance, we knocked down bFGF expression in SUM159and BT549 cells by stable bFGF shRNA transfection
(Fig. 3a). Cells transfected with bFGF or control shRNA
were treated for 2 days with doxorubicin as in Fig. 1a. The
number of doxorubicin-enriched chemo-residual cells on
day 7 was significantly decreased in bFGF shRNA transfec-
tants compared to control shRNA transfectants (Fig. 3b, c).
Moreover, bFGF shRNA-transfected chemo-residual cells
formed dramatically fewer colonies after chemotherapy
removal than control shRNA transfectants (Fig. 3d, e).
Similar results were observed in two TN breast cancer
cell lines (SUM159, BT549; Fig. 3d, e). These results
indicate that bFGF is necessary for the survival of
chemo-residual tumor cells after doxorubicin challenge
and for their subsequent proliferation upon chemotherapy
withdrawal.Nuclear bFGF promotes the survival of chemo-residual
tumor cells and subsequent colony formation
To determine which bFGF isoform facilitates chemo-
residual tumor cell survival and colony formation in our
model, we transfected bFGF shRNA-expressing cells
with a vector expressing 18-kDa rat bFGF, 23-kDa rat
bFGF, or an empty control vector (Fig. 4a). The 18-kDa
and 23-kDa rat bFGF constructs exhibit 97 % and 82 %
homology with human 18-kDa and 24-kDa nuclear bFGF,
respectively [30]. The addback of the 23-kDa rat nuclear
bFGF, but not the 18-kDa rat cytosolic bFGF, to bFGF
shRNA transfectants increased the number of chemo-
residual tumor cells to that observed in control cells
(Fig. 4b). Likewise addback of the 23-kDa bFGF isoform
restored the ability of bFGF shRNA-transfected chemo-
residual cells to establish colonies (Fig. 4c, d) following
short-term doxorubicin treatment. Of note, similar
transfection of SUM159 cells expressing the control
shRNA did not influence cell viability (data not shown).
Fig. 2 Chemo-residual triple-negative (TN) breast cancer cells from a short-term chemotherapy treatment model exhibit increased expression of
a nuclear isoform of basic fibroblast growth factor (bFGF). a Increased bFGF RNA in chemo-residual SUM159 cells after doxorubicin treatment as
described in Fig. 1a. Total RNA was extracted from parental and chemo-residual cells. bFGF mRNA expression was quantified by qRT-PCR, and is
shown as fold increase relative to β-actin. Error bars represent SD, n = 3, **p <0.01, two-tailed Student’s t test. b Left panel: increased expression of
nuclear, but not cytosolic bFGF in chemo-residual SUM159 cells after doxorubicin or docetaxel treatment (as described in Fig. 1a). Nuclear or
cytosolic protein was extracted from parental and chemo-residual cells. Equivalent amounts were immunoblotted with bFGF, Lamin A, or GAPDH
antibody, followed by IrDye-conjugated secondary antibodies. Protein bands were detected by infrared imaging. Right panel: protein bands from
three independent trials (doxorubicin treatment, as described in Fig. 1a) were quantified using Image J software (NIH), and the relative ratio of
nuclear bFGF to loading control is shown for parental and chemo-residual SUM159 cells. Error bars represent SD, n = 3, ***p <0.001, two-tailed
Student’s t test. c SUM159 and BT549 cells were treated with doxorubicin as described in Fig. 1a. Parental and chemo-residual cells were fixed
and stained with Hoechst (blue) and bFGF antibody (red) to demonstrate the increased nuclear localization of bFGF in chemo-residual TN breast
cancer cells. Magnification ×400.
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weight (nuclear) bFGF, but not low molecular weight
(cytosolic) bFGF, is sufficient to maintain the viability of
chemo-residual tumor cells and promote subsequent col-
ony growth after chemotherapy withdrawal.
bFGF regulates DNA-PK expression/activity and is
associated with accelerated DNA double strand break
repair in chemo-residual TN tumor cells
Elevated DNA repair activity is associated with chemo-
resistance in many tumors [31–34]. To compare the
DNA double-strand break (DSB) repair capability, we
re-challenged untreated parental cells and chemo-residual
cells with doxorubicin (a DNA-damaging agent) for 3 h and
examined their recovery by neutral comet assay. As shown
(Fig. 5a, b) the percent cells with comet tails returned to
baseline quicker in chemo-residual cells than in parental
cells. Similar results were observed in both SUM159 (Fig. 5a)
and BT549 (Fig. 5b) chemo-resistance models. These
data indicate that chemo-residual TN tumor cellsfrom our short-term chemotherapy treatment model
repaired DNA strand breaks more quickly than paren-
tal cells.
DNA-PK is the key protein responsible for non-
homologous end joining (NHEJ) of DNA DSBs. Over-
expression of bFGF in HeLa cells drives the expression
and activation of DNA-PKCS [20]. To determine whether
DNA-PKCS is a downstream target of nuclear bFGF in our
TN breast cancer chemo-resistance model, we determined
the expression level of DNA-PKCS in chemotherapy-
enriched TN tumor cells. Chemo-residual TN tumor cells
expressed increased levels of both DNA-PKCS and phospho
(Ser-2056)-DNA-PKCS, representing the activated form of
DNA-PKCS [35] (Fig. 5c).
Inhibition of DNA DSB repair by a selective DNA-PK
inhibitor decreases the survival of chemo-residual tumor
cells and subsequent colony formation
NU7441 is a specific inhibitor of DNA-PK with 100-fold
selectivity for DNA-PK, compared to other PI3K kinase
Fig. 3 Basic fibroblast growth factor (bFGF) knockdown in triple-negative (TN) breast tumor cells reduces the number of chemo-residual cells and
blocks subsequent colony formation. a SUM159 and BT549 cells were transfected stably with a bFGF shRNA or control (ctrl) shRNA. The knock-
down of nuclear bFGF was confirmed by immunoblotting equivalent amounts of nuclear extract with bFGF antibody. Protein loading was
accessed using Lamin A antibody. Protein bands were quantified using Image J software (NIH), and the relative ratio of bFGF to loading control is
shown for each lane. b and c SUM159 cells (b) and BT549 cells (c) transfected stably with a bFGF shRNA or control shRNA were treated with
doxorubicin as described in Fig. 1a. Upper panel: pictures of remaining chemo-residual cells were taken on day 7. Magnification ×20. Lower panel:
numbers of chemotherapy (chemo)-enriched chemo-residual cells on day 7 were determined by trypan blue exclusion; n = 3, error bars represent
SD, ***p <0.001, two-tailed Student’s t test. d and e SUM159 cells (d) and BT549 cells (e) transfected stably with a bFGF shRNA or control (ctrl)
shRNA were treated with doxorubicin as described in Fig. 1a. Upper panel: colonies (containing >50 cells) were quantified on the indicated days.
Error bars represent SD, n = 3, **p <0.01, ***p <0.001, two-tailed Student’s t test. Lower panel: colonies were fixed and stained with crystal violet
on day 22 (SUM159 cell) and day 24 (BT549 cell). Similar results were obtained in at least three independent trials
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PK inhibition reduces TN chemo-residual tumor cell
survival and regrowth, we simultaneously treated
SUM159 TN breast tumor cells with doxorubicin and
NU7441 at either of two non-cytotoxic concentrations[36]. NU7441 significantly decreased the number of
chemo-residual cells (Fig. 6a) and subsequent colony for-
mation (Fig. 6b) in a concentration-dependent manner.
Previous preclinical studies indicate that the DNA-PK
inhibitor NU7441 synergizes with chemotherapy to
Fig. 4 Transfection of basic fibroblast growth factor (bFGF) knockdown cells with 23-kDa bFGF (nuclear bFGF) vector restores chemo-residual
cell survival and subsequent colony formation. a bFGF shRNA-transfected SUM159 cells were transfected with vectors expressing low molecular
weight (LMW) (cytosolic) bFGF, high molecular weight (HMW) (nuclear) bFGF, or pCI as a vector control (ctrl). The expression of addback
constructs in stable transfectants was confirmed and compared to control shRNA-transfected cells by immunoblotting equivalent amounts of
nuclear (upper two lanes) or cytosolic (lower two lanes) extract with bFGF antibody. Protein loading was assessed using Lamin A or GAPDH
antibody. b SUM159 cells expressing control shRNA, bFGF shRNA, or bFGF shRNA plus indicated addback constructs were treated with doxorubicin
as described in Fig. 1a. The number of chemo-residual cells was determined on day 7 by trypan blue exclusion. Error bars represent SD, n = 3,
***p <0.001, two-tailed Student’s t test. c Colonies (containing >50 cells) were quantified on the indicated days. Error bars represent SD, n = 3,
***p <0.001, two-tailed Student’s t test. d Colonies were fixed and stained with crystal violet on day 20. Similar results were obtained in at least
three independent trials
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results suggest the importance of testing the efficacy of
combination therapy (NU7441 + chemotherapy) for TNBC
in future preclinical studies.
Nuclear bFGF drives accelerated DNA repair and
DNA-PKcs expression in chemo-residual TN tumor cells
We next investigated the effects of bFGF knockdown on
DNA repair in chemotherapy-challenged TN breast tumor
cells. Twenty-four hours after doxorubicin challenge,
SUM159 cells expressing a bFGF shRNA had a similar
level of DNA damage to that of cells expressing a control
shRNA, with approximately 70 % of cells having a comet
tail (Fig. 7a). However, control shRNA-expressing cells
exhibited more rapid DNA repair than bFGF shRNA trans-
fectants, with only approximately 30 % of control shRNA-
expressing cells having comet tails at 48 h post challenge
(compared to approximately 60 % of bFGF shRNA-
expressing cells having comet tails at this time) (Fig. 7a). Todetermine which bFGF isoform drives repair in these cells,
we next performed comet assays on knockdown cells
reconstituted with low molecular weight (LMW) or high
molecular weight (HMW) bFGF. As shown in Fig. 7b,
bFGF knockdown cells exhibited significantly slower
DNA repair than control cells. Moreover, expression
of HMW bFGF, but not LMW bFGF in knockdown
cells restored DNA repair to the level observed in
control shRNA cells (Fig. 7b).
Based on our observation that DNA repair in chemo-
residual cells was associated with increased nuclear bFGF
and increased DNA-PKcs levels, we next investigated
effects of bFGF knockdown on DNA-PKcs expression.
bFGF knockdown significantly decreased the DNA-PKCS
protein level in chemotherapy-enriched tumor cells, indi-
cating upstream regulation of DNA-PKCS by bFGF
(Fig. 7c). Expression of HMW bFGF, but not LMW bFGF,
in bFGF knockdown cells increased DNA-PKcs levels
(Fig. 7d). In contrast, expression of HMW bFGF did
Fig. 5 Chemo-residual tumor cells exhibit higher DNA repair capability and increased expression/phosphorylation of DNA-dependent protein
kinase (DNA-PKCS). a Left panel: SUM159 chemo-residual cells and parental (untreated) cells were re-challenged with doxorubicin (Dox) (1 μg/ml)
for 3 h. Fresh medium was added after chemotherapy removal. DNA damage at sequential time points after chemotherapy treatment was
analyzed by neutral comet assay. Representative images are shown at each time point. Cells scored as comet tail-positive are indicated with
red arrows in the 72-h (72h) time frame. Right panel: the percentage of cells with comet tails at the indicated time points was quantified with a
fluorescence microscope. Error bars represent SD, n = 3 fields. Significance of data points at 24h, 48h and 72 h was determined relative to data
reported at 0h for the indicated cell population (*p <0.05, **p <0.01, ***p <0.001, two-tailed Student’s t test). Cells scored as comet tail-positive
are indicated with red arrows in the 72h time frame. b. Left panel: BT549 chemo-residual cells and parental (untreated) cells were challenged with
Dox (0.5 μg/ml) for 4 h. DNA damage was assessed at the indicated times using the neutral comet assay as in a. Right panel: the percentage of
cells with comet tails at the indicated time points was quantified as in a. Cells scored as comet tail-positive are indicated with red arrows in the
72h time frame. c Left and middle panel: SUM159 cells (left) and BT549 cells (middle) were treated with Dox as described in Fig. 1a. Nuclear
protein from parental and chemo-residual cells was extracted. Equivalent amounts were immunoblotted with phospho (Ser 2056)-DNA-PKCS,
DNA-PKCS or Lamin A antibody. Right panel: protein bands from three independent trials (SUM159 cells treated with Dox as described in
Fig. 1a) were quantified, and the relative ratio of DNA-PKCS to loading control is shown. Error bars represent SD, n = 3, **p <0.01, two-tailed
Student’s t test
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cells (data not shown). Collectively, these results sug-
gest that chemo-residual tumor cells support a bFGF/
DNA-PK signaling axis that confers accelerated DNA
DSB repair capability, allowing them to survive chemo-
therapy challenge.Percentage of nuclear bFGF-expressing tumor cells is
increased or maintained in a subset of residual tumors
from TN breast cancer patients
To validate our findings in patients with TN breast cancer,
we optimized an immunohistochemistry (IHC) protocol
for detecting nuclear and cytosolic bFGF in formalin-fixed,
Fig. 6 Selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) decreases the survival of chemo-residual tumor cells and subsequent
colony formation. a SUM159 cells were treated with doxorubicin (1 μg/ml) plus dimethyl sulfoxide (DMSO) or a selective DNA-PK inhibitor
(NU7441), at a non-cytotoxic concentration [36] (1 μM or 5 μM) for 2 days, as described in Fig. 1a. Fresh medium was added after treatment
removal. Upper panel: pictures of chemo-residual cells were taken on day 7. Magnification ×40. Lower panel: Chemo-residual cell number
on day 7 was determined by trypan blue exclusion. Error bars represent SD, n = 3, *p <0.05, **p <0.01, two-tailed Student’s t test. b
Colonies (containing >50 cells) were quantified on days 14, 16, and 18, respectively. Error bars represent SD, n = 3. Significance was determined relative
to DMSO-treated cells at each time point using the two-tailed Student’s t test (*p <0.05, ***p <0.001). Similar results were obtained in at least three
independent trials
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nine patients with TN breast cancer that exhibited an
incomplete pathologic response to neoadjuvant
chemotherapy treatment. Matched samples from pa-
tients with TN breast cancer (Fig. 8), obtained before
and after neoadjuvant chemotherapy treatment, were
stained with bFGF antibody. As shown in Table 1, in
five of nine patients, the percentage of nuclear bFGF+
tumor cells increased or remained the same in the
post treatment samples compared to those obtainedpre-treatment. In contrast, in four of nine patients
with TNBC, the percentage of nuclear bFGF+ tumor
cells decreased post treatment. These data demon-
strate that nuclear bFGF-positive cells are enriched in
a subset of patients with TN breast cancer following
neoadjuvant chemotherapy treatment. Of note, the
percentage of cytosolic bFGF+ tumor cells did not fol-
low the same trends pre-treatment versus post treatment
as did the percentage of nuclear bFGF+ tumor cells
for these patients (data not shown).
Fig. 7 Nuclear basic fibroblast growth factor (bFGF) drives DNA repair and DNA-dependent protein kinase catalytic subunit (DNA-PKcs) expression.
a Left panel: BT549 cells transfected with bFGF shRNA or control (ctrl) shRNA were challenged with doxorubicin (Dox) (0.25 μg/ml) for 2 h. Fresh medium
was added after chemotherapy removal. DNA damage at sequential time points after chemotherapy treatment was analyzed by neutral comet assay.
Representative images are shown for each time point. Cells scored as comet tail-positive are indicated with red arrows in the 48-h time frame. Right panel:
percentage of cells with comet tails at indicated time points was quantified with a fluorescence microscope. Error bars represent SD, n = 3 fields
(each field containing >50 cells). Significance of data points at 24 and 48 h was determined relative to data reported at 0 h for the indicated cell
population (*p <0.05, **p <0.01, ***p <0.001, two-tailed Student’s t test). b SUM159 cells expressing control shRNA, bFGF shRNA, or bFGF shRNA plus
indicated addback constructs (as in Fig. 4a) were challenged with doxorubicin (0.25 μg/ml) for 2 h. Fresh medium was added after chemotherapy
removal. DNA damage at sequential time points after chemotherapy treatment was analyzed by neutral comet assay. Percentage of cells with comet tails
at the indicated time points was quantified with a fluorescence microscope. Error bars represent SD, n = 3 fields (each field containing >50 cells).
Significance of data points at 24 and 48 h was determined relative to data reported at 0 h for the indicated cell population (*p <0.05, **p <0.01, ***p
<0.001, two-tailed Student’s t test). c SUM159 and BT549 cells transfected with bFGF shRNA or ctrl shRNA were treated with doxorubicin as in Fig. 1a.
Nuclear protein from chemo-residual cells was extracted. Equivalent amounts were immunoblotted with DNA-PKCS and lamin A antibodies. Protein bands
were quantified, and the relative ratio of DNA-PKCS to loading control is shown for each lane. d Left panel: bFGF shRNA-transfected SUM159 cells
expressing indicated addback constructs were treated with doxorubicin as in Fig. 1a. Nuclear protein from chemo-residual cells was extracted. Equivalent
amounts were immunoblotted with DNA-PKCS and Lamin A antibodies. Right panel: protein bands from three independent trials were quantified and the
relative ratio of DNA-PKCS to loading control is shown for each line. Error bars represent SD, n = 3, **p <0.01, two-tailed Student’s t test
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Fig. 8 Nuclear basic fibroblast growth factor (bFGF) expression is increased in a subset of triple-negative (TN) breast cancers post neoadjuvant
chemotherapy treatment. bFGF immunohistochemistry was performed on matched tumor tissues obtained from a patient with TN breast cancer
before (pre-chemotherapy) and after (post-chemotherapy) neoadjuvant chemotherapy (docetaxel/cyclophosphamide) treatment. Magnification ×200
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Previous chemotherapy selection models have shown the
relevance of cancer stem-like cells in TN breast cancer
chemo-resistance [27, 28]. In one of these studies,
HIF-1α was shown to be a central determinant of TN
cancer stem-like cell chemo-resistance [27]. Our model is
distinct from these studies in identifying a chemo-
resistant TN tumor cell subpopulation enriched after 2
days of chemotherapy treatment followed by a rest period
(6 days) during which chemotherapy is removed. We
propose that this model is pertinent to the drug holiday
experienced in patients between chemotherapy cycles.
Notably chemo-resistant cells from our model differ from
those arising after continuous chemotherapy treatment.
First, chemo-residual TN tumor cells from our model doTable 1 Nuclear bFGF expression in triple-negative breast tumors b
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ously implicated in cancer stem-cell chemo-resistance
[28], is downregulated in chemo-residual TN tumor cells
from our model (Fig. 1e, f ). We hypothesize that continu-
ous chemotherapy treatment is necessary to maintain a
cancer stem-like cell population, a topic of current investi-
gation in our laboratory. In contrast, our short-term
chemotherapy treatment model identifies a chemo-resistant
population that is maintained after chemotherapy removal,
and that exhibits increased DNA repair capability driven by
a nuclear bFGF signaling axis.
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juvant chemotherapy treatment [38]. It is important to
note, however, that microarray analyses will not identify
chemo-resistance markers regulated at the translational
or post-translation level. Our study is unique in studying
proteins that are upregulated in chemo-residual TN
tumor cells. Using a short-term chemotherapy enrichment
model, we have identified a nuclear bFGF isoform, the
expression of which is dependent on cap-independent
protein translation, that determines survival of TN chemo-
residual tumor cells.
Expression of nuclear versus cytosolic bFGF isoforms
is determined by alternative translation pathways.
Whereas cytosolic bFGF isoforms are regulated by
cap-dependent translation, nuclear bFGF isoforms are
regulated by cap-independent translation. Notably, we ob-
served increased protein levels of nuclear but not cytosolic
bFGF isoforms in chemo-residual tumor cells. Our data
suggest that chemo-residual tumor cells may support cap-
independent translation, driving expression of nuclear
bFGF and DNA repair. We are currently addressing this
important hypothesis. Ultimately, it may be possible to
eliminate these chemo-residual tumor cells by targeting
the cap-independent translation pathway.
Previous studies indicate that tumor resistance to
anti-angiogenic therapy is associated with increased
expression of cytosolic FGF, which is able to restore
tumor angiogenesis [10–15]. Accordingly, we were sur-
prised to observe upregulation of nuclear bFGF isoforms,
but not cytosolic bFGF isoforms, in chemo-residual tumor
cells. Our studies suggest that nuclear bFGF may drive TN
breast cancer resistance in a manner independent of
angiogenesis.
We observed that chemo-residual cells, relative to
parental SUM159 tumor cells, express increased levels
of both the 22-kDa and the 24-kDa nuclear forms of
bFGF (Fig. 1d). In order to determine whether both
nuclear bFGF isoforms are critical to our model, we
performed addback studies using a 23-kDa rat nuclear
bFGF construct (exhibiting 82 % homology with human
24-kDa nuclear bFGF). This 23-kDa bFGF isoform alone
was able to restore chemo-resistance by promoting
chemo-residual cell survival and regrowth in SUM159
cells expressing bFGF shRNA. Our data indicate that the
survival function of this 23-kDa bFGF isoform relates to
its ability to drive DNA repair.
We also observed that bFGF RNA levels are increased
in chemo-residual tumor cells relative to parental tumor
cells (Fig. 1c). Identifying signaling pathways that increase
bFGF transcription/mRNA stability in chemo-residual
cells has the potential to identify rational methods for
targeting these chemo-resistant tumor cells. Of note,
previous studies indicate that hypoxia drives bFGF tran-
scription in an HIF-1-dependent manner [39]. However, wedid not see HIF-1 expression elevated in chemotherapy-
enriched tumor cells (Fig. 2e), suggesting an alterna-
tive driver of bFGF mRNA expression in chemo-residual
tumor cells.
Our work identifies DNA-PKCS as a downstream target
of nuclear bFGF in chemo-residual TN tumor cells.
DNA-PKCS has previously been implicated in therapy
resistance [31–34]. Long term chemotherapy selection
models have been shown to select for chemo-resistant
tumor cells with increased DNA-PKCS expression/activity
[34, 40]. The current study is unique in identifying a
nuclear growth factor (nuclear bFGF) in chemo-residual
tumor cells that drives DNA repair and DNA-PKCS
expression. Notably, nuclear bFGF did not increase
DNA-PKcs mRNA levels, as assessed by real-time PCR
(data not shown). Further work is needed to determine
the mechanism by which nuclear bFGF increases
DNA-PKcs expression/activity. In addition, we are investi-
gating the ability of nuclear bFGF to activate other DNA
repair pathways.
We also found that a small molecule inhibitor of
DNA-PKCS reduced both the number of chemo-residual
tumor cells (Fig. 7) and the number of colonies evolving
after chemotherapy withdrawal (Fig. 7) in our in vitro
model of TN breast cancer chemo-resistance. This activity
may be attributed to multiple reported activities of
DNA-PK. This DNA-PK inhibitor likely reduces the
number of chemo-residual tumor cells by blocking
DNA repair, leading to increased tumor cell apoptosis.
However, this inhibitor may also chemo-sensitize TN
tumor cells by inhibiting a recently reported, non-
conventional activity for DNA-PK, namely its ability
to induce AKT-dependent cell survival [41]. Finally,
DNA-PK is a critical regulator of mitosis [42]. Thus, it is
possible that inhibiting DNA-PK in our model prevents
the transition of chemo-residual tumor cells to prolifera-
tive colonies.
Nuclear-localized EGF receptor is a central determinant
of DNA-PK activity [43]. Based on this knowledge, in
addition to our current findings, it is intriguing to speculate
that nuclear bFGF may control DNA-PKCS expression/
activity in a manner dependent on a nuclear bFGF recep-
tor, a topic of current investigation. This possibility is sup-
ported by the literature, which demonstrates that nuclear
FGF cooperates with a nuclear FGF receptor to drive gene
transcription in neurons [44]. Identifying a bFGF receptor
that drives nuclear bFGF/DNA-PK signaling has the
potential to define a logical therapeutic strategy (i.e.,
combining chemotherapy with an FGF receptor small
molecule inhibitor) to eliminate chemo-residual TN
breast cancer cells, thus preventing tumor recurrence.
Our studies of TN breast cancer samples obtained
before and after neoadjuvant chemotherapy treatment
demonstrate that a subset of these patients exhibit an
Li et al. Breast Cancer Research  (2015) 17:91 Page 15 of 16increased percentage of nuclear bFGF-positive cells
post treatment. These data validate our in vitro findings,
showing that chemotherapy enriches for nuclear
bFGF-positive cells. All of these patients received either
anthracycilne or anthracyline + taxane therapy, and exhib-
ited an incomplete pathologic response. While 56 % of
matched samples exhibited increased or sustained nuclear
bFGF-positive cells, 44 % of matched samples exhibited
reduced nuclear bFGF-positive cells post neoadjuvant
chemotherapy. Considering that multiple TN breast
cancer subtypes have been identified [45], we hypothesize
that nuclear bFGF-positive cells may only be enriched in a
subset of TN breast cancer subtypes. The role of homolo-
gous recombination deficiency (HRD), commonly medi-
ated by loss of BRCA1/2 activity, in chemo-responsiveness
is not well-defined, and is actively being investigated
(NCT01982448). The HRD/BRCA status of TN breast
cancer patients may also influence whether a nuclear
bFGF/DNA-PK signaling axis determines chemotherapy
resistance. We hypothesize that with follow up the 56 % of
patients with increased or sustained percentage of nuclear
bFGF-positive cells will exhibit future tumor recurrence.
These pilot data underscore the importance of performing
a large-scale prospective study of nuclear bFGF expression
in TN breast cancer cases before and after neoadjuvant
chemotherapy treatment, controlling for BRCA status and
TN breast cancer subtype. These follow-up studies have
the potential to identify a novel biomarker in a subset of
TN breast cancer patients that predicts chemotherapy
resistance and future tumor recurrence. In addition,
identifying nuclear bFGF as a determinant of chemo-
resistance in a subset of TN breast cancers will establish a
logical therapeutic strategy for chemo-sensitizing tumors
in these patients.
Conclusions
Using a short-term chemotherapy enrichment model, we
demonstrated a critical role for nuclear bFGF in TN
breast cancer chemotherapy resistance. Notably, previous
continuous chemotherapy selection models did not
identify nuclear bFGF as a driver of TN breast cancer
chemo-resistance. To begin to demonstrate the rele-
vance of our findings to the clinic, we showed that
nuclear bFGF-positive tumor cells were increased or
maintained in the majority of patients with TN breast
cancer post neoadjuvant chemotherapy treatment.
Follow-up studies are needed to determine if nuclear
bFGF expression in TN breast cancer cells predicts an
incomplete pathologic response and/or future tumor
recurrence in patients with TN breast cancer.
Chemotherapy remains the core therapy for TN breast
cancer and studies of new agents will likely continue
to be done in combination with chemotherapy for the
foreseeable future. Our studies suggest that nuclear bFGFmaintains survival of a chemo-resistant subpopulation
that then drives metastatic recurrence. Developing
therapies that target this mechanism may be essential
for overcoming this chemo-resistance and reducing
TN breast cancer-associated mortality.
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